Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Survival and failure types after radiation therapy of vulvar cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Forecasting lung cancer incidence, mortality, and prevalence to year 2030

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Iatrogenic cerebral radiation necrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Detection and characterization of lung cancer using cell-free DNA fragmentomes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0-38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.

Original languageEnglish
JournalClinical and Translational Radiation Oncologi
Volume13
Pages (from-to)24-28
Number of pages5
ISSN2405-6308
DOIs
Publication statusPublished - Nov 2018

ID: 55856519